CPT® Code 81439

Hereditary cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes (eg, DSG2, MYBPC3, MYH7, PKP2, TTN)

The CPT® Code 81439 refers to a genomic sequence analysis panel specifically designed for hereditary cardiomyopathies, which include conditions such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC). This laboratory test is crucial for identifying genomic sequence mutations that are associated with these hereditary heart conditions. HCM is characterized by left ventricular hypertrophy that occurs without any predisposing factors, leading to symptoms such as syncope (fainting), shortness of breath, palpitations, and chest pain. DCM, on the other hand, results in left ventricular enlargement and a reduction in the heart's ability to contract effectively, which can manifest as heart failure, arrhythmias, and an increased risk of thromboembolic events. ARVC is marked by structural abnormalities in the heart and irregular rhythms, where myocardial tissue is replaced by fibrofatty tissue, potentially leading to symptoms like syncope, palpitations, and even sudden cardiac arrest. The test involves obtaining a blood sample through a procedure known as venipuncture, which is reported separately. Once the blood sample is collected, DNA is extracted and fragmented, followed by the enrichment of targeted gene segments using a technique called capture hybridization. The analysis employs massively parallel next-generation sequencing to detect mutations by comparing the gene segments and identifying similarities or differences. This genomic sequencing analysis panel must include the sequencing of at least five cardiomyopathy-related genes, such as DSG2, MYBPC3, MYH7, PKP2, and TTN. The results of this genetic testing can be instrumental in confirming a diagnosis, identifying at-risk family members or silent carriers, and guiding treatment planning or genetic counseling.